Logo

BARDA Signs a Multi-Year Agreement with Regeneron for its REGN-EB3 for National Preparedness

Share this

BARDA Signs a Multi-Year Agreement with Regeneron for its REGN-EB3 for National Preparedness

Shots:

  • Regeneron will be responsible to deliver treatment doses for six years post-approval of product from the FDA- will receive compensation of ~$10M & average of $67M/year in 2021 and each for the next five years (2022-2026) respectively
  • In 2019- the PALM trial evaluated REGN-EB3 vs ZMapp conducted in the Democratic Republic of the Congo- was stopped as the REGN-EB3 crossed the pre-specified superiority threshold for preventing death in Ebola patients
  • Regeneron's REGN-EB3 is a novel anti-viral Ab cocktail developed using its VelociSuite platform in collaboration and funding provided by BARDA. The product is under priority review by the US FDA with PDUFA date Oct 25- 2020

Ref: BusinessWire | Image: Behnace

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions